Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura.
In eight patients carotid angiography was required for evaluation of transient neurological attacks. Cerebral blood flow results, angiography and clinical observations subsequently suggested the diagnosis of migraine. We measured plasma concentrations of substance P(SP), neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) in repeated blood samples obtained from the carotid artery and the internal jugular vein in conjunction with cerebral angiography followed by 4 to 6 repeated recordings of regional cerebral blood flow (rCBF) with the intracarotid Xenon-133 injection technique. This technique is known to induce attacks of migraine with aura in many sufferers. Four patients developed aura symptoms. In three this was succeeded by throbbing headache. Typical, migraine-related, focal hypoperfusion occurred in conjunction with the aura symptoms. The remaining four patients had no symptoms or rCBF changes. There were no systematic or statistically significant changes over time in arterial-venous plasma concentrations or in the release rates of any of the peptides. All migraineurs had an overall elevated mean CGRP value compared to control values from the literature. The overall plasma levels of the potent vasoconstrictor NPY were higher (p < 0.10) in the group that developed symptoms and rCBF changes (136 pmol/l) than in the non-symptomatic group (97 pmol/l). The difference in NPY levels could perhaps be associated with the focal rCBF decrease seen in the attack group.
Friberg
L
L
Department of Clinical Physiology and Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark.
Olesen
J
J
Olsen
T S
TS
Karle
A
A
Ekman
R
R
Fahrenkrug
J
J
D000328:Adult; D002116:Calcitonin / Q000097:blood / Q000378:metabolism; D015740:Calcitonin Gene-Related Peptide / Q000097:blood / Q000378:metabolism; D002343:Carotid Artery, Internal; D002533:Cerebral Angiography / Q000009:adverse effects; D002560:Cerebrovascular Circulation; D005260:Female; D006429:Hemiplegia / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D002546:Ischemic Attack, Transient / Q000000981:diagnostic imaging; D007601:Jugular Veins; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000097:blood / Q000209:etiology / Q000503:physiopathology*; D009478:Neuropeptide Y / Q000097:blood / Q000378:metabolism; D009479:Neuropeptides / Q000097:blood / Q000378:metabolism*; D010292:Paresthesia / Q000209:etiology / Q000503:physiopathology*; D011877:Radionuclide Imaging; D013373:Substance P / Q000097:blood / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000097:blood / Q000378:metabolism; D014786:Vision Disorders / Q000209:etiology / Q000503:physiopathology*; D014980:Xenon Radioisotopes
D009478:Neuropeptide Y; D009479:Neuropeptides; D014980:Xenon Radioisotopes; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D002116:Calcitonin; D015740:Calcitonin Gene-Related Peptide